Posted by Michael Wonder on 02 Apr 2023
TG Therapeutics announces positive CHMP opinion for Briumvi (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis in adults
31 March 2023 - TG Therapeutics today announced that the CHMP of the EMA has issued a positive opinion recommending the approval of Briumvi (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.
Briumvi is the first and only anti-CD20 monoclonal antibody approved in the US for adult patients with relapsing forms of multiple sclerosis that can be administered in a one hour infusion following the starting dose.
